Neural Therapeutics Inc. NURL
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -505.81% | -137.11% | 118.14% | -747.48% | -10.58% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,161.54% | 94.39% | -124.04% | 9,198.11% | -191.38% |
| Change in Net Operating Assets | 172.29% | 150.46% | -315.03% | -81.23% | 21.28% |
| Cash from Operations | -3.02% | -54.89% | 87.84% | -3,615.38% | -642.86% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -200.00% | -- |
| Total Debt Repaid | -- | -- | 95.97% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -87.62% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -- | -- | -1,053.66% | -98.74% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.02% | 41.85% | 66.88% | -159.12% | 45,771.43% |